TUVP (Transurethral vaporisation of the prostate) pips TURP (transurethral resection of the prostate) in NHS study of BPH (benign prostatic hyperplasia) electrosurgery technologies
This article was originally published in Clinica
Executive Summary
Transurethral vaporisation of the prostate (TUVP) has outperformed the NHS's standard treatment of bladder outflow obstruction in men with benign prostatic hyperplasia (BPH) - transurethral resection of the prostate (TURP) - in a nine-year health technology assessment (HTA) of the two technologies in the UK.
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.